SVV-024
/ Seneca Therap
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
February 08, 2021
Seneca Therapeutics Expands Product Pipeline Adding Six New SVV-001 Armed Constructs Targeting TEM 8 Expression
(Businesswire)
- “Seneca Therapeutics, Inc…announced today the expansion of its R&D pipeline with six new armed gene therapy/oncolytic constructs directed against important cancer targets and indications. STI also announced an SVV-001 Armed Construct program developing precision medicine constructs expressing patient-specific Neo-antigens…Animal studies for each product are anticipated to begin in 2Q21. The SVV-001 Armed Construct for Neo-antigens program plans to use patient specific neo-antigens to take advantage of the rapid two-week development cycle for SVV-001 Armed Constructs.”
Pipeline update • Preclinical • Oncology
1 to 1
Of
1
Go to page
1